| Hazard Information | Back Directory | [Uses]
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin.html" class="link-product" target="_blank">Vancomycin (HY-B0671) or Linezolid.html" class="link-product" target="_blank">Linezolid (HY-10394)[1][2][3]. | [in vivo]
Suvratoxumab (5, 15, 45 mg/kg; i.p.; single) increases survival rates in an immunocompromised murine pneumonia model[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis reduces pulmonary damage and increases macrophage phagocytosis in mice[1].
Suvratoxumab (15 mg/kg; i.p.; single) prophylaxis improves the effectiveness of antibiotic (vancomycin or linezolid) treatment in mice[1]. | Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 5, 15, 45 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Resulted in dose-dependent increases in survival rates and reductions in bacterial CFU. |
| Animal Model: | Specific-pathogen-free, 7- to 9-week-old, female C57BL/6J mice (immunocompromised pneumonia model)[1]. | | Dosage: | 15 mg/kg | | Administration: | Intraperitoneal injection; single | | Result: | Prophylaxis protected the lungs of S. aureus-infected immunocompromised mice from α toxin-mediated damage. |
| [References]
[1] Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59(8):4526-32. DOI:10.1128/AAC.00510-15
[2] Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61(1):e01020-16. DOI:10.1128/AAC.01020-16
[3] Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. DOI:10.1074/jbc.M114.601328 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|